ICER To Open Cost Effectiveness Models To Drug Firms During Review Process
Executive Summary
Institute for Clinical and Economic Review launching pilot program that allows drug assessment models to be inspected, but not manipulated, by manufacturers.
You may also be interested in...
New Migraine Drugs May Not Be Cost Effective In Patients With Other Options, ICER Suggests
Draft cost effectiveness report released by the Institute for Clinical and Economic Review uses $8,500 annual cost for Aimovig and fremanezumab as a "placeholder" price.
Open-Source Rx Value Model Designed To Encourage 'More Productive' Discussions
Industry-funded Open-Source Value Project aims to disseminate tools to the marketplace for customized value assessments, as opposed to offering a specific estimate of value for pricing and coverage decisions.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.